While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider ...

Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for ...

Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.

Fees are Below Average compared to funds in the same category. Franklin Biotechnology Discovery Fund has an expense ratio of 1.01 percent. Risk is Above Average compared to funds in the same category ...

Integrated consulting approach streamlines pathway from concept to commercialization NEW YORK, NY, UNITED STATES, April ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

Why Enveda, Faeth Therapeutics, Gilgamesh Pharma, and Argo Biopharma are among the most innovative companies in biotech right now. The Most Innovative Companies in biotech reflect a year in which ...

A small biotech was forced to being winding down its operations after the FDA abruptly postponed a key meeting for four ...

One of the world’s largest biotech companies is closing its only office in the Bay Area. Pfizer is shutting down its office ...

The multipronged organization has a lab space on the working waterfront and an academy, the Gloucester Biotechnology Academy, ...